biostudies-literatureGlampedakis EPfizer811https://www.ebi.ac.uk/biostudies/studies/S-EPMC8540382biostudies-literatureUnknown7(10)<h4>Background</h4>Antifungal combination treatment is frequently administered for invasive mold infections (IMIs) after allogeneic hematopoietic cell transplantation (HCT). Here, we describe the indications, timing, and outcomes of combination antifungal therapy in post-HCT IMI.<h4>Methods</h4>A single-center, 10-year, retrospective cohort study including all adult HCT recipients with proven/probable IMI between 1 January 2010 and 1 January 2020 was conducted.<h4>Results</h4>During the study period, 515 patients underwent HCT, of whom 47 (9.1%) presented 48 IMI episodes (46 patients with one IMI episode and 1 patient with two separate IMI episodes): 33 invasive aspergillosis (IA) and 15 non-IA IMIs. Almost half (51%) of the patients received at least one course of an antifungal combinatioJournal of fungi (Basel, Switzerland)Real-Life Considerations on Antifungal Treatment Combinations for the Management of Invasive Mold Infections after Allogeneic Cell Transplantation.PMC854038259276319 - WP248505659276319 – WP2485056Glampedakis EMasouridi-Levrat SVan Delden CGiannotti FMamez ACChalandon YRoth RNeofytos DfalseReal-Life Considerations on Antifungal Treatment Combinations for the Management of Invasive Mold Infections after Allogeneic Cell Transplantation.<h4>Background</h4>Antifungal combination treatment is frequently administered for invasive mold infections (IMIs) after allogeneic hematopoietic cell transplantation (HCT). Here, we describe the indications, timing, and outcomes of combination antifungal therapy in post-HCT IMI.<h4>Methods</h4>A single-center, 10-year, retrospective cohort study including all adult HCT recipients with proven/probable IMI between 1 January 2010 and 1 January 2020 was conducted.<h4>Results</h4>During the study period, 515 patients underwent HCT, of whom 47 (9.1%) presented 48 IMI episodes (46 patients with one IMI episode and 1 patient with two separate IMI episodes): 33 invasive aspergillosis (IA) and 15 non-IA IMIs. Almost half (51%) of the patients received at least one course of an antifungal combinatio2021-01-01T00:00:00Z2021 Sep2025-08-31T03:08:49.644Z2025-04-04T10:55:28.035ZS-EPMC85403823468223310.3390/jof7100811